Advertisement
NVS vs PFE
Which Stock Would AI Choose? Novartis AG (NVS) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- Novartis (NVS) outperforms Pfizer (PFE) year-to-date with +8.87% returns versus +7.51%, reflecting stronger momentum in recent market activity.
- NVS boasts a larger market capitalization of approximately $280 billion compared to PFE's $150 billion, underscoring its scale in the pharmaceutical sector.
- PFE offers a higher dividend yield at 6.53% versus NVS's 3.23%, appealing to income-focused investors.
- Both stocks exhibit low volatility with betas of 0.52 for NVS and 0.31 for PFE (beta measures sensitivity to market movements).
- NVS reported robust Q1 growth drivers up 34% in constant currency (cc, adjusted for currency fluctuations), offsetting generic erosion.
- PFE emphasizes pipeline catalysts in oncology and obesity ahead of its upcoming Q1 earnings.
Introduction
Novartis AG (NVS) and Pfizer Inc. (PFE), two pharmaceutical powerhouses, offer investors exposure to innovative therapies in oncology, immunology, and cardiovascular areas. This stock comparison analyzes their recent performance, business drivers, and market positioning amid ongoing generic pressures and pipeline advancements. Traders seeking defensive plays in healthcare, with dividends and growth potential, may find value in evaluating relative momentum and stability. Both companies navigate sector challenges like patent cliffs while advancing R&D pipelines, making this head-to-head relevant for portfolio diversification in volatile markets.
NVS Overview and Recent Performance
Novartis AG (NVS), a Swiss-based global healthcare leader, focuses on innovative medicines across cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. In recent weeks, NVS shares traded around $146, with a 52-week range of $104.93 to $170.46 and year-to-date gains of 8.87%. Q1 2026 results showed net sales of $13.1 billion (-5% cc), impacted by U.S. generic erosion, but priority brands like Kisqali (+55%), Pluvicto, Kesimpta, Leqvio, and Scemblix drove 34% cc growth. Key developments include Health Canada approval for Fabhalta, positive Phase III data for remibrutinib, FDA nods for Cosentyx expansions, and the $12 billion Avidity acquisition bolstering neuromuscular pipeline. These catalysts, alongside reaffirmed full-year guidance for low single-digit sales growth, have supported resilient sentiment despite a core operating income dip (-14% cc). Market cap stands at $280 billion, P/E at 21 (trailing twelve months, TTM), with EPS (TTM) of $6.98.
PFE Overview and Recent Performance
Pfizer Inc. (PFE), a U.S. multinational, maintains a broad portfolio in oncology, vaccines, rare diseases, and inflammation. Shares recently hovered near $26, within a 52-week range of $21.97 to $28.75, posting year-to-date returns of 7.51%. Recent market activity featured dips amid broader sector pressures, with the stock down modestly over the past month. Anticipation builds for Q1 2026 earnings on May 5, expected at $0.74 EPS and $13.82 billion in revenue, driven by Vyndaqel, Eliquis, Prevnar, Padcev, and oncology assets like Ibrance. Positive notes include FDA approvals like Veppanu with Arvinas for breast cancer and Guggenheim's Buy rating citing pipeline catalysts in obesity and oncology. Cost-cutting and margin improvements offset COVID-era declines, supporting $13.6 billion in cash. Market cap is $150 billion, P/E 19.36 (TTM), with EPS (TTM) $1.36 and strong free cash flow of $13.43 billion.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 351 available bots that trade thousands of tickers across various styles, strategies, and timeframes. These bots employ AI/ML for technical and fundamental analysis, trend following, swing trading, and multi-agent systems with take-profit/stop-loss (TP/SL) corridors like 3%/2%. Performance highlights include annualized returns ranging from +23.53% to +163.10%, win rates of 51.30% to 88.33%, profit factors up to 11.70, and profit-to-drawdown ratios as high as 17.02, with average trade durations from 1 day to 49 days. Focused on hot sectors like semiconductors and data centers, they demonstrate adaptability to current conditions. Explore these bots to potentially enhance your trading with data-driven strategies tailored to market dynamics.
Head-to-Head Comparison
Both NVS and PFE operate in pharmaceuticals but differ in focus: NVS emphasizes specialized innovative therapies post its generics spin-off, while PFE retains broader exposure including vaccines and consumer health divestitures. Growth drivers favor NVS with 34% cc priority brand surge versus PFE's reliance on established blockbusters amid patent risks. Recent momentum tilts to NVS (1-year +33%), though PFE shows pipeline promise in obesity. Risk factors include generic erosion for both, but PFE's higher debt/equity (78%) contrasts NVS's efficiency. Sector exposure overlaps in oncology/immunology, yet NVS leads in stability (ROE 35%). Sentiment leans positive for NVS on acquisitions, with PFE attractive for yield.
Tickeron AI Verdict
Tickeron’s AI currently leans toward NVS based on superior trend consistency, YTD outperformance, and robust pipeline catalysts like remibrutinib and Avidity integration, positioning it favorably amid healthcare volatility. PFE remains compelling probabilistically for dividend stability and upcoming readouts, but NVS exhibits stronger relative momentum and growth trajectory in recent market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Hold and PFE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVS’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- NVS’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVS’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- NVS’s TA Score: 6 bullish, 3 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
Price Growth
NVS (@Pharmaceuticals: Major) experienced а +3.51% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.81%. For the same industry, the average monthly price growth was +7.81%, and the average quarterly price growth was +4.81%.
Reported Earning Dates
NVS is expected to report earnings on Jul 21, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.81% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| NVS | PFE | NVS / PFE | |
| Capitalization | 288B | 148B | 195% |
| EBITDA | 22.4B | 17.2B | 130% |
| Gain YTD | 13.252 | 7.919 | 167% |
| P/E Ratio | 21.71 | 19.85 | 109% |
| Revenue | 56.6B | 63.3B | 89% |
| Total Cash | 6.98B | 13.1B | 53% |
| Total Debt | 47B | 63.7B | 74% |
NVS | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 6 | 100 | |
SMR RATING 1..100 | 27 | 78 | |
PRICE GROWTH RATING 1..100 | 48 | 34 | |
P/E GROWTH RATING 1..100 | 36 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as NVS (6). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that NVS’s stock grew significantly faster than PFE’s over the last 12 months.
NVS's SMR Rating (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (78). This means that NVS’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as NVS (48). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as PFE (42). This means that NVS’s stock grew similarly to PFE’s over the last 12 months.
| NVS | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 39% | 4 days ago 54% |
| Momentum ODDS (%) | 4 days ago 49% | 4 days ago 61% |
| MACD ODDS (%) | 4 days ago 56% | 4 days ago 41% |
| TrendWeek ODDS (%) | 4 days ago 53% | 4 days ago 56% |
| TrendMonth ODDS (%) | 4 days ago 48% | 4 days ago 50% |
| Advances ODDS (%) | 11 days ago 51% | 4 days ago 56% |
| Declines ODDS (%) | 14 days ago 45% | 13 days ago 58% |
| BollingerBands ODDS (%) | 4 days ago 54% | 4 days ago 54% |
| Aroon ODDS (%) | 4 days ago 45% | 4 days ago 60% |
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.80% | ||
| BMY - PFE | 59% Loosely correlated | -1.56% | ||
| MRK - PFE | 55% Loosely correlated | -2.79% | ||
| AMGN - PFE | 53% Loosely correlated | -1.31% | ||
| NVS - PFE | 52% Loosely correlated | -0.99% | ||
| BIIB - PFE | 51% Loosely correlated | -0.70% | ||
More | ||||